Extended thromboprophylaxis after hip or knee replacement

Orthopedics

Volumn 26, Issue 2 SUPPL., 2003, Pages

  Friedman, Richard J ^a  

^a Charleston Orthopaedic Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ARDEPARIN; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PLACEBO; WARFARIN;

ARTERY DISEASE; ARTICLE; BLEEDING; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; HEART INFARCTION; HOSPITAL DISCHARGE; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; META ANALYSIS; OUTPATIENT CARE; POSTTHROMBOSIS SYNDROME; RISK MANAGEMENT; STROKE; SYMPTOMATOLOGY; THROMBOEMBOLISM; THROMBOSIS PREVENTION; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT;

ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; DRUG ADMINISTRATION SCHEDULE; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; POSTOPERATIVE COMPLICATIONS; THROMBOSIS; TIME FACTORS;

EID: 0037322314     PISSN: 01477447     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Geerts WH, Heit JA, Pineo GF, et al. Prevention of venous thromboemobolism. Chest. 2001; 119(suppl):132S-175S.
2. Clagett GP, Anderson FA, Heit J, Levine MN, Wheeler HB. Prevention of venous thromboembolism. Chest. 1995; 108(suppl):312S-334S.
3. Planes A, Vochelle N, Darmon J-Y, Fagola M, Bellaud M, Huet Y. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. Lancet. 1996; 348:224-228.
4. Bergqvist D, Benoni G, Bjorgell O, et al. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med. 1996; 335:696-700.
5. Seagroatt V, Tan HS, Goldcare M, Bulstrode C, Nugent I, Gijl L. Effective total hip replacement: incidence, emergency readmission rate, and postoperative mortality. Br Med J. 1991; 303:1431-1435.
6. Johnson R, Green JR, Charnley J. Pulmonary embolism and its prophylaxis following the Charley total hip replacement. Clin Orthop. 1977; 127:123-132.
7. Kher A, Samana MM. Low-molecular-weight heparins: weeks or months instead of days of treatment. Clin Appl Thromb Hemost. 2001; 7:314-320.
8. Prandoni P, Lensing AWA, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med. 1996; 125:1-7.
9. Serafini S, Beltrametti C, Siragusa S, Barone M. Piovella F. Port-thrombotic syndrome after asymptotic post-operative deep vein thrombosis: an inception cohort study [abstract]. Thromb Haemost. 1997; 77(suppl):718. Abstract PS-2930.
10. McNally MA, McAlinden MG, O'Connell BM, Mollan RAB. Postphlebitic syndrome after hip arthroplasty. 43 patients followed at least 5 years. Acta Orthop Scand. 1994; 65:595-598.
11. Comp PC, Spiro TE, Friedman RJ, et al. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. J Bone Joint Surg Am. 2001; 83:336-345.
12. Eikelboom JW, Quinlan DJ, Douketis JD. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet. 2001; 358:9-15.
13. Hull RD, Pineo GF, Francis C, et al. Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital versus in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients. A double-blind, randomized comparison. Arch Intern Med. 2000; 160:2008-2215.
14. Dahl OE, Andreassen G, Aspelin T, et al. Prolonged thromboprophylaxis following hip replacement surgery - results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin). Thromb Haemost. 1997;77:26-31.
15. Lassen MR, Borris LC, Anderson BS, et al. Efficacy and safety of prolonged thromboprophylaxis with a low-molecular-weight heparin (dalteparin) after total hip arthroplasty - the Danish Prolonged Prophylaxis (DaPP) Study. Thromb Res. 1998;89:281-287.
16. Heit JA, Elliott CG, Trowbridge AA, Morrey BF, Gent M, Hirsh J, for the Ardeparin Arthroplasty Study Group. Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2000; 132;853-861.
17. Manganelli D, Pazzagli M, Mazzantini D, et al. Prolonged prophylaxis with unfractionated heparin is effective to reduce delayed deep vein thrombosis in total hip replacement. Respiration. 1998; 65:369-374.
18. Haentjens P. Venous thromboembolism after total hip arthroplasty: a review of incidence and prevention during hospitalization and after hospital discharge. Acta Orthop Belg. 2000;66:1-8.
19. Cohen AT, Bailey CS, Alikhan R, Cooper DJ. Extended thromboprophylaxis with low-molecular-weight heparin reduces symptomatic venous thromboembolism following limb arthroplasty - a meta-analysis [letter]. Thromb Haemost. 2001; 85:940-941.
20. Bergqvist D. Enoxparin. A pharmacoeconomic review of its use in the prevention and treatment of venous thromboembolism and in acute coronary syndromes. Pharmacoeconomics. 2002; 20:225-243.
21. Detournay B, Planes A, Vochelle N, Fagnani F. Cost effectiveness of a low-molecular-weight heparin in prolonged prophylaxis against deep vein thrombosis after total hip replacement. Pharmacoeconomics. 1998; 13(1 pt 1):81-89.
22. Bergqvist D, Jönsson B. Cost-effectivenes of prolonged out-of-hospital following total hip replacement. Haemostasis. 2000; 30(suppl 2):130-135.
23. Marchetti M, Liberato NL, Ruperto N, Barosi G. Long-term cost-effectiveness of low-molecular-weight heparin versus unfractionated heparin for the prophylaxis of venous thromboembolism in elective hip replacement. Haematologica. 1999; 84:730-737.
24. Friedman RJ, Dunsworth GA. Cost analyses of extended prophylaxis with enoxaparin after hip arthroplasty. Clin Orthop. 2000; 370:171-182.
25. Caprini JA, Arcelus JI, Hasty JH, Tamhane AC, Fabrega F. Clinical assessment of venous Thromb Hemost. 1991; 17(suppl 3):304-312.